MX2021012305A - Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. - Google Patents

Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.

Info

Publication number
MX2021012305A
MX2021012305A MX2021012305A MX2021012305A MX2021012305A MX 2021012305 A MX2021012305 A MX 2021012305A MX 2021012305 A MX2021012305 A MX 2021012305A MX 2021012305 A MX2021012305 A MX 2021012305A MX 2021012305 A MX2021012305 A MX 2021012305A
Authority
MX
Mexico
Prior art keywords
bicyclic heteroaryl
inhibitors
ectonucleotide pyrophosphatase
compounds
heteroaryl derivatives
Prior art date
Application number
MX2021012305A
Other languages
English (en)
Inventor
Klaus Klumpp
Ronald Hawley
Original Assignee
Riboscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riboscience Llc filed Critical Riboscience Llc
Publication of MX2021012305A publication Critical patent/MX2021012305A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La presente divulgación proporciona ciertos compuestos heteroarílicos bicíclicos que inhiben la actividad enzimática de la ectonucleótido pirofosfatasa/fosfodiesterasa 1 (ENPP1) y que son, por consiguiente, útiles para el tratamiento de enfermedades y afecciones moduladas al menos en parte por ENPP1. En algunas realizaciones, los compuestos heteroarílicos bicíclicos incluyen los de Fórmula (I): (ver Fórmula) En la presente también se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
MX2021012305A 2019-04-12 2020-04-10 Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. MX2021012305A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833455P 2019-04-12 2019-04-12
US201962881111P 2019-07-31 2019-07-31
PCT/US2020/027700 WO2020210649A1 (en) 2019-04-12 2020-04-10 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Publications (1)

Publication Number Publication Date
MX2021012305A true MX2021012305A (es) 2021-11-12

Family

ID=70465561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012305A MX2021012305A (es) 2019-04-12 2020-04-10 Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.

Country Status (22)

Country Link
US (1) US20220362266A1 (es)
EP (2) EP4249070A3 (es)
JP (1) JP2022526432A (es)
KR (1) KR20210151873A (es)
CN (1) CN114040915A (es)
AU (1) AU2020272034A1 (es)
CA (1) CA3136443A1 (es)
DK (1) DK3952995T3 (es)
ES (1) ES2960987T3 (es)
FI (1) FI3952995T3 (es)
HR (1) HRP20231413T1 (es)
HU (1) HUE064377T2 (es)
IL (1) IL286966A (es)
LT (1) LT3952995T (es)
MX (1) MX2021012305A (es)
PL (1) PL3952995T3 (es)
PT (1) PT3952995T (es)
RS (1) RS64792B1 (es)
SG (1) SG11202110888QA (es)
SI (1) SI3952995T1 (es)
TW (1) TW202103708A (es)
WO (1) WO2020210649A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022164249A1 (ko) * 2021-01-29 2022-08-04 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
WO2022197734A1 (en) * 2021-03-16 2022-09-22 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN116444544A (zh) * 2022-01-10 2023-07-18 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
WO2006125592A2 (en) * 2005-05-24 2006-11-30 Lek Pharmaceuticals D.D. Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl)methyl)-imidazole, dihydroimidazole or benzimidazole derivatives
CN100427488C (zh) * 2005-10-21 2008-10-22 上海东升新材料有限公司 腺嘌呤类衍生物及其合成方法
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
RU2547441C2 (ru) * 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
US11225655B2 (en) * 2010-04-16 2022-01-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
EP2710006A1 (en) * 2011-05-17 2014-03-26 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
AU2015329955A1 (en) * 2014-10-08 2017-05-11 Thomas Helledays Stiftelse For Medicinsk Forskning Heterocyclic compounds as DCTPP1 modulators
BR112018000041A2 (pt) * 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
MX2019007256A (es) * 2016-12-22 2019-11-18 Mavupharma Inc Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano.
WO2018119325A1 (en) * 2016-12-22 2018-06-28 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
US10487084B2 (en) * 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
WO2019096113A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种氘代的含硼的化合物及药物组合物和用途

Also Published As

Publication number Publication date
AU2020272034A1 (en) 2021-10-28
US20220362266A1 (en) 2022-11-17
TW202103708A (zh) 2021-02-01
EP4249070A2 (en) 2023-09-27
SG11202110888QA (en) 2021-10-28
SI3952995T1 (sl) 2023-12-29
PT3952995T (pt) 2023-10-25
IL286966A (en) 2021-12-01
ES2960987T3 (es) 2024-03-07
HUE064377T2 (hu) 2024-03-28
PL3952995T3 (pl) 2024-03-11
RS64792B1 (sr) 2023-11-30
JP2022526432A (ja) 2022-05-24
CA3136443A1 (en) 2020-10-15
DK3952995T3 (da) 2023-10-30
WO2020210649A1 (en) 2020-10-15
CN114040915A (zh) 2022-02-11
HRP20231413T1 (hr) 2024-02-16
EP3952995B1 (en) 2023-09-20
KR20210151873A (ko) 2021-12-14
EP3952995A1 (en) 2022-02-16
FI3952995T3 (fi) 2023-10-26
LT3952995T (lt) 2023-11-10
EP4249070A3 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2021012305A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2022013941A (es) Inhibidores de imino sulfanona de enpp1.
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
PH12020552207A1 (en) Pyrazole derivatives as malt1 inhibitors
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
MX2016006744A (es) Inhibidores de tirosina cinasa de bruton.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
CR20220667A (es) Derivados de tetrazol como inhibidores de trpa1
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.